MINNEAPOLIS, September 17, 2015 — Invenshure, LLC, a technology incubator and venture catalyst, announced that it has launched its second fund, seeking $50 million to provide additional support to its current portfolio companies and to pursue new opportunities in precision medicine and health IT.
Troy Kopischke, Co-CEO and Managing Director of Invenshure stated, “As data becomes more ubiquitous and deep learning tools more prevalent, opportunities in bioinformatics and genetics will create better outcomes for patients and impressive returns for investors. It’s an exploding marketplace.”
“The launch of this second fund validates the success of our business model and reinforces our desire to make a measurable difference on the world—utilizing technology to unlock efficiencies in healthcare,” said Danny Cunagin, Co-CEO and Managing Director of Invenshure.
Invenshure has experienced rapid growth since its inception in 2011. It has built several portfolio companies including Exosite, a cloud-based data platform company offering Internet of Things (IoT) products and services; Imbio, a company developing fully automated diagnostic tools; OneOme, a pharmacogenomics company launched with the Mayo Clinic; and Flywheel, a data management platform company simplifying collaboration and reproducibility in scientific research.
About Invenshure, LLC
Invenshure’s process is to scour university research labs for novel and disruptive technologies ready for commercialization. Invenshure’s experienced team partners with top scientists, physicians, and researchers from the most trusted institutions in healthcare and technology. The company focuses on high-growth sectors including biotech, genomics, healthcare IT, diagnostics, cloud computing technologies, and wireless technologies. For more information, visit http://invenshure.com.